Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 314

1.

Low Abundance of Circulating Tumor DNA in Localized Prostate Cancer.

Hennigan ST, Trostel SY, Terrigino NT, Voznesensky OS, Schaefer RJ, Whitlock NC, Wilkinson S, Carrabba NV, Atway R, Shema S, Lake R, Sweet AR, Einstein DJ, Karzai F, Gulley JL, Chang P, Bubley GJ, Balk SP, Ye H, Sowalsky AG.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.19.00176. Epub 2019 Sep 9.

2.

ZBTB7A Mediates the Transcriptional Repression Activity of the Androgen Receptor in Prostate Cancer.

Han D, Chen S, Han W, Gao S, Owiredu JN, Li M, Balk SP, He HH, Cai C.

Cancer Res. 2019 Oct 15;79(20):5260-5271. doi: 10.1158/0008-5472.CAN-19-0815. Epub 2019 Aug 23.

PMID:
31444154
3.

Morphological and Molecular Changes in Juvenile Normal Human Fibroblasts Exposed to Simulated Microgravity.

Buken C, Sahana J, Corydon TJ, Melnik D, Bauer J, Wehland M, Krüger M, Balk S, Abuagela N, Infanger M, Grimm D.

Sci Rep. 2019 Aug 15;9(1):11882. doi: 10.1038/s41598-019-48378-9.

4.

Clinical counseling on sun protection and indoor tanning avoidance: A survey of current practices among U.S. health care providers.

Holman DM, Qin J, Gottschlich EA, Balk SJ.

Prev Med. 2019 Sep;126:105783. doi: 10.1016/j.ypmed.2019.105783. Epub 2019 Jul 17.

PMID:
31325525
5.

VISAGE Reveals a Targetable Mitotic Spindle Vulnerability in Cancer Cells.

Patterson JC, Joughin BA, Prota AE, Mühlethaler T, Jonas OH, Whitman MA, Varmeh S, Chen S, Balk SP, Steinmetz MO, Lauffenburger DA, Yaffe MB.

Cell Syst. 2019 Jul 24;9(1):74-92.e8. doi: 10.1016/j.cels.2019.05.009. Epub 2019 Jul 10.

6.

Copy number alterations and copy-neutral loss of heterozygosity in Ukrainian patients with primary myelofibrosis.

Poluben L, Bryke CR, Hsu Y, Shumeiko O, Neumerzhitska L, Klimuk B, Rybchenko L, Klymenko S, Balk SP, Fraenkel PG.

Exp Oncol. 2019 Mar;41(1):53-56.

PMID:
30932413
7.

Targeting the androgen receptor and overcoming resistance in prostate cancer.

Einstein DJ, Arai S, Balk SP.

Curr Opin Oncol. 2019 May;31(3):175-182. doi: 10.1097/CCO.0000000000000520.

PMID:
30893145
8.

Association of prostate cancer SLCO gene expression with Gleason grade and alterations following androgen deprivation therapy.

Alsinnawi M, Zhang A, Bianchi-Frias D, Burns J, Cho E, Zhang X, Sowalsky A, Ye H, Slee AE, True L, Porter C, Taplin ME, Balk S, Nelson PS, Montgomery RB, Mostaghel EA.

Prostate Cancer Prostatic Dis. 2019 Mar 19. doi: 10.1038/s41391-019-0141-6. [Epub ahead of print]

9.

ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer.

Cato L, de Tribolet-Hardy J, Lee I, Rottenberg JT, Coleman I, Melchers D, Houtman R, Xiao T, Li W, Uo T, Sun S, Kuznik NC, Göppert B, Ozgun F, van Royen ME, Houtsmuller AB, Vadhi R, Rao PK, Li L, Balk SP, Den RB, Trock BJ, Karnes RJ, Jenkins RB, Klein EA, Davicioni E, Gruhl FJ, Long HW, Liu XS, Cato ACB, Lack NA, Nelson PS, Plymate SR, Groner AC, Brown M.

Cancer Cell. 2019 Mar 18;35(3):401-413.e6. doi: 10.1016/j.ccell.2019.01.008. Epub 2019 Feb 14.

PMID:
30773341
10.

ACKR3 Regulation of Neuronal Migration Requires ACKR3 Phosphorylation, but Not β-Arrestin.

Saaber F, Schütz D, Miess E, Abe P, Desikan S, Ashok Kumar P, Balk S, Huang K, Beaulieu JM, Schulz S, Stumm R.

Cell Rep. 2019 Feb 5;26(6):1473-1488.e9. doi: 10.1016/j.celrep.2019.01.049.

11.

Initiation and Evolution of Early Onset Prostate Cancer.

Russo JW, Balk SP.

Cancer Cell. 2018 Dec 10;34(6):874-876. doi: 10.1016/j.ccell.2018.11.010.

PMID:
30537509
12.

Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.

Sharp A, Coleman I, Yuan W, Sprenger C, Dolling D, Rodrigues DN, Russo JW, Figueiredo I, Bertan C, Seed G, Riisnaes R, Uo T, Neeb A, Welti J, Morrissey C, Carreira S, Luo J, Nelson PS, Balk SP, True LD, de Bono JS, Plymate SR.

J Clin Invest. 2019 Jan 2;129(1):192-208. doi: 10.1172/JCI122819. Epub 2018 Nov 26.

13.

Characteristics of myeloproliferative neoplasms in patients exposed to ionizing radiation following the Chernobyl nuclear accident.

Poluben L, Puligandla M, Neuberg D, Bryke CR, Hsu Y, Shumeiko O, Yuan X, Voznesensky O, Pihan G, Adam M, Fraenkel E, Rasnic R, Linial M, Klymenko S, Balk SP, Fraenkel PG.

Am J Hematol. 2019 Jan;94(1):62-73. doi: 10.1002/ajh.25307. Epub 2018 Oct 31.

14.

Objective Performance Goals for Surgical Treatment of Critical Limb Ischemia.

Zimmermann A, Balk S, Kuehnl A, Eckstein HH.

Ann Vasc Surg. 2019 Feb;55:104-111. doi: 10.1016/j.avsg.2018.07.050. Epub 2018 Oct 2.

PMID:
30287288
15.

Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer.

Russo JW, Gao C, Bhasin SS, Voznesensky OS, Calagua C, Arai S, Nelson PS, Montgomery B, Mostaghel EA, Corey E, Taplin ME, Ye H, Bhasin M, Balk SP.

Cancer Res. 2018 Nov 15;78(22):6354-6362. doi: 10.1158/0008-5472.CAN-18-0687. Epub 2018 Sep 21.

PMID:
30242112
16.

Phosphorylation of androgen receptor serine 81 is associated with its reactivation in castration-resistant prostate cancer.

Russo JW, Liu X, Ye H, Calagua C, Chen S, Voznesensky O, Condulis J, Ma F, Taplin ME, Einstein DJ, Balk SP, Chen S.

Cancer Lett. 2018 Dec 1;438:97-104. doi: 10.1016/j.canlet.2018.09.014. Epub 2018 Sep 11.

PMID:
30217568
17.

Contribution of Adrenal Glands to Intratumor Androgens and Growth of Castration-Resistant Prostate Cancer.

Mostaghel EA, Zhang A, Hernandez S, Marck BT, Zhang X, Tamae D, Biehl HE, Tretiakova M, Bartlett J, Burns J, Dumpit R, Ang L, Matsumoto AM, Penning TM, Balk SP, Morrissey C, Corey E, True LD, Nelson PS.

Clin Cancer Res. 2019 Jan 1;25(1):426-439. doi: 10.1158/1078-0432.CCR-18-1431. Epub 2018 Sep 4.

PMID:
30181386
18.

Addressing Cancer Chemotherapeutic Toxicity, Resistance, and Heterogeneity: Novel Theranostic Use of DNA-Encoded Small Molecule Libraries.

Kolodny G, Li X, Balk S.

Bioessays. 2018 Oct;40(10):e1800057. doi: 10.1002/bies.201800057. Epub 2018 Aug 12. Review.

PMID:
30101540
19.

Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis.

Arai S, Jonas O, Whitman MA, Corey E, Balk SP, Chen S.

Clin Cancer Res. 2018 Nov 1;24(21):5458-5470. doi: 10.1158/1078-0432.CCR-18-0549. Epub 2018 Jul 18.

PMID:
30021909
20.

BMX-Mediated Regulation of Multiple Tyrosine Kinases Contributes to Castration Resistance in Prostate Cancer.

Chen S, Cai C, Sowalsky AG, Ye H, Ma F, Yuan X, Simon NI, Gray NS, Balk SP.

Cancer Res. 2018 Sep 15;78(18):5203-5215. doi: 10.1158/0008-5472.CAN-17-3615. Epub 2018 Jul 16.

21.

Calcium signaling: an underlying link between cardiac disease and carcinogenesis.

Xu X, Balk SP, Isaacs WB, Ma J.

Cell Biosci. 2018 Jun 8;8:39. doi: 10.1186/s13578-018-0236-0. eCollection 2018. No abstract available.

22.

Impaired Local Translation of β-actin mRNA in Ighmbp2-Deficient Motoneurons: Implications for Spinal Muscular Atrophy with respiratory Distress (SMARD1).

Surrey V, Zöller C, Lork AA, Moradi M, Balk S, Dombert B, Saal-Bauernschubert L, Briese M, Appenzeller S, Fischer U, Jablonka S.

Neuroscience. 2018 Aug 21;386:24-40. doi: 10.1016/j.neuroscience.2018.06.019. Epub 2018 Jun 19.

PMID:
29928949
23.

Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations.

Sowalsky AG, Ye H, Bhasin M, Van Allen EM, Loda M, Lis RT, Montaser-Kouhsari L, Calagua C, Ma F, Russo JW, Schaefer RJ, Voznesensky OS, Zhang Z, Bubley GJ, Montgomery B, Mostaghel EA, Nelson PS, Taplin ME, Balk SP.

Cancer Res. 2018 Aug 15;78(16):4716-4730. doi: 10.1158/0008-5472.CAN-18-0610. Epub 2018 Jun 19.

24.

CLEC10A Is a Specific Marker for Human CD1c+ Dendritic Cells and Enhances Their Toll-Like Receptor 7/8-Induced Cytokine Secretion.

Heger L, Balk S, Lühr JJ, Heidkamp GF, Lehmann CHK, Hatscher L, Purbojo A, Hartmann A, Garcia-Martin F, Nishimura SI, Cesnjevar R, Nimmerjahn F, Dudziak D.

Front Immunol. 2018 Apr 27;9:744. doi: 10.3389/fimmu.2018.00744. eCollection 2018.

25.

Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.

Luo J, Attard G, Balk SP, Bevan C, Burnstein K, Cato L, Cherkasov A, De Bono JS, Dong Y, Gao AC, Gleave M, Heemers H, Kanayama M, Kittler R, Lang JM, Lee RJ, Logothetis CJ, Matusik R, Plymate S, Sawyers CL, Selth LA, Soule H, Tilley W, Weigel NL, Zoubeidi A, Dehm SM, Raj GV.

Eur Urol. 2018 May;73(5):715-723. doi: 10.1016/j.eururo.2017.11.038. Epub 2017 Dec 16. Review.

26.

Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions.

Mohammad OS, Nyquist MD, Schweizer MT, Balk SP, Corey E, Plymate S, Nelson PS, Mostaghel EA.

Cancers (Basel). 2017 Dec 6;9(12). pii: E166. doi: 10.3390/cancers9120166. Review.

27.

BDNF/trkB Induction of Calcium Transients through Cav2.2 Calcium Channels in Motoneurons Corresponds to F-actin Assembly and Growth Cone Formation on β2-Chain Laminin (221).

Dombert B, Balk S, Lüningschrör P, Moradi M, Sivadasan R, Saal-Bauernschubert L, Jablonka S.

Front Mol Neurosci. 2017 Oct 30;10:346. doi: 10.3389/fnmol.2017.00346. eCollection 2017.

28.

Counseling on Sun Protection and Indoor Tanning.

Balk SJ, Gottschlich EA, Holman DM, Watson M.

Pediatrics. 2017 Dec;140(6). pii: e20171680. doi: 10.1542/peds.2017-1680. Epub 2017 Nov 10.

29.

Isolation and Functional Use of Human NKT Cells.

Exley MA, Wilson SB, Balk SP.

Curr Protoc Immunol. 2017 Nov 1;119:14.11.1-14.11.20. doi: 10.1002/cpim.33.

PMID:
29091262
30.

Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide.

Calagua C, Russo J, Sun Y, Schaefer R, Lis R, Zhang Z, Mahoney K, Bubley GJ, Loda M, Taplin ME, Balk SP, Ye H.

Clin Cancer Res. 2017 Nov 15;23(22):6812-6822. doi: 10.1158/1078-0432.CCR-17-0807. Epub 2017 Sep 11.

31.

Epitaxy of advanced nanowire quantum devices.

Gazibegovic S, Car D, Zhang H, Balk SC, Logan JA, de Moor MWA, Cassidy MC, Schmits R, Xu D, Wang G, Krogstrup P, Op Het Veld RLM, Zuo K, Vos Y, Shen J, Bouman D, Shojaei B, Pennachio D, Lee JS, van Veldhoven PJ, Koelling S, Verheijen MA, Kouwenhoven LP, Palmstrøm CJ, Bakkers EPAM.

Nature. 2017 Aug 23;548(7668):434-438. doi: 10.1038/nature23468.

PMID:
28836603
32.

Testicular vs adrenal sources of hydroxy-androgens in prostate cancer.

Zang T, Taplin ME, Tamae D, Xie W, Mesaros C, Zhang Z, Bubley G, Montgomery B, Balk SP, Mostaghel EA, Blair IA, Penning TM.

Endocr Relat Cancer. 2017 Aug;24(8):393-404. doi: 10.1530/ERC-17-0107. Epub 2017 Jun 29.

33.

Environmental Risks to Children: Prioritizing Health Messages in Pediatric Practice.

Galvez MP, Balk SJ.

Pediatr Rev. 2017 Jun;38(6):263-279. doi: 10.1542/pir.2015-0165. Review. No abstract available. Erratum in: Pediatr Rev. 2017 Sep;38(9):442.

PMID:
28572135
34.

Association Between Androgen Receptor Splice Variants and Prostate Cancer Resistance to Abiraterone and Enzalutamide.

Bubley GJ, Balk SP.

J Clin Oncol. 2017 Jul 1;35(19):2103-2105. doi: 10.1200/JCO.2017.72.8808. Epub 2017 Apr 17. No abstract available.

PMID:
28414609
35.

Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer.

Mostaghel EA, Cho E, Zhang A, Alyamani M, Kaipainen A, Green S, Marck BT, Sharifi N, Wright JL, Gulati R, True LD, Loda M, Matsumoto AM, Tamae D, Penning TN, Balk SP, Kantoff PW, Nelson PS, Taplin ME, Montgomery RB.

Clin Cancer Res. 2017 Aug 15;23(16):4592-4601. doi: 10.1158/1078-0432.CCR-16-2245. Epub 2017 Apr 7.

36.

Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity.

Patnaik A, Swanson KD, Csizmadia E, Solanki A, Landon-Brace N, Gehring MP, Helenius K, Olson BM, Pyzer AR, Wang LC, Elemento O, Novak J, Thornley TB, Asara JM, Montaser L, Timmons JJ, Morgan TM, Wang Y, Levantini E, Clohessy JG, Kelly K, Pandolfi PP, Rosenblatt JM, Avigan DE, Ye H, Karp JM, Signoretti S, Balk SP, Cantley LC.

Cancer Discov. 2017 Jul;7(7):750-765. doi: 10.1158/2159-8290.CD-16-0778. Epub 2017 Mar 8.

37.

Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial.

Exley MA, Friedlander P, Alatrakchi N, Vriend L, Yue S, Sasada T, Zeng W, Mizukami Y, Clark J, Nemer D, LeClair K, Canning C, Daley H, Dranoff G, Giobbie-Hurder A, Hodi FS, Ritz J, Balk SP.

Clin Cancer Res. 2017 Jul 15;23(14):3510-3519. doi: 10.1158/1078-0432.CCR-16-0600. Epub 2017 Feb 13.

38.

Neoadjuvant Enzalutamide Prior to Prostatectomy.

Montgomery B, Tretiakova MS, Joshua AM, Gleave ME, Fleshner N, Bubley GJ, Mostaghel EA, Chi KN, Lin DW, Sanda M, Novotny W, Wu K, Kantoff PW, Marck BT, Plymate S, Balk SP, Nelson PS, Matsumoto AM, Lis RT, Kibel A, Haas GP, Krivoshik A, Hannah A, Taplin ME.

Clin Cancer Res. 2017 May 1;23(9):2169-2176. doi: 10.1158/1078-0432.CCR-16-1357. Epub 2016 Nov 9.

39.

Challenges in Interpreting Germline Mutations in BARD1 and ATM in Breast and Ovarian Cancer Patients.

DeLeonardis K, Sedgwick K, Voznesensky O, Matloff E, Hofstatter E, Balk S, Tung N.

Breast J. 2017 Jul;23(4):461-464. doi: 10.1111/tbj.12764. Epub 2017 Jan 31.

PMID:
28139868
40.

Gleason Score 7 Prostate Cancers Emerge through Branched Evolution of Clonal Gleason Pattern 3 and 4.

Sowalsky AG, Kissick HT, Gerrin SJ, Schaefer RJ, Xia Z, Russo JW, Arredouani MS, Bubley GJ, Sanda MG, Li W, Ye H, Balk SP.

Clin Cancer Res. 2017 Jul 15;23(14):3823-3833. doi: 10.1158/1078-0432.CCR-16-2414. Epub 2017 Jan 24.

41.

Positive feedback loop mediated by protein phosphatase 1α mobilization of P-TEFb and basal CDK1 drives androgen receptor in prostate cancer.

Liu X, Gao Y, Ye H, Gerrin S, Ma F, Wu Y, Zhang T, Russo J, Cai C, Yuan X, Liu J, Chen S, Balk SP.

Nucleic Acids Res. 2017 Apr 20;45(7):3738-3751. doi: 10.1093/nar/gkw1291.

42.

Reprogramming to resist.

Kelly K, Balk SP.

Science. 2017 Jan 6;355(6320):29-30. doi: 10.1126/science.aam5355. No abstract available.

PMID:
28059730
43.

Spaceflight-Relevant Challenges of Radiation and/or Reduced Weight Bearing Cause Arthritic Responses in Knee Articular Cartilage.

Willey JS, Kwok AT, Moore JE, Payne V, Lindburg CA, Balk SA, Olson J, Black PJ, Walb MC, Yammani RR, Munley MT.

Radiat Res. 2016 Oct;186(4):333-344. Epub 2016 Sep 7.

PMID:
27602483
44.

Androgen Receptor Tumor Suppressor Function Is Mediated by Recruitment of Retinoblastoma Protein.

Gao S, Gao Y, He HH, Han D, Han W, Avery A, Macoska JA, Liu X, Chen S, Ma F, Chen S, Balk SP, Cai C.

Cell Rep. 2016 Oct 18;17(4):966-976. doi: 10.1016/j.celrep.2016.09.064.

45.

A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer.

McKay RR, Werner L, Mostaghel EA, Lis R, Voznesensky O, Zhang Z, Marck BT, Matsumoto AM, Domachevsky L, Zukotynski KA, Bhasin M, Bubley GJ, Montgomery B, Kantoff PW, Balk SP, Taplin ME.

Clin Cancer Res. 2017 Feb 15;23(4):935-945. doi: 10.1158/1078-0432.CCR-16-0987. Epub 2016 Sep 28. Erratum in: Clin Cancer Res. 2017 Jul 15;23 (14 ):3970.

46.

Mutation Profiling Indicates High Grade Prostatic Intraepithelial Neoplasia as Distant Precursors of Adjacent Invasive Prostatic Adenocarcinoma.

Gerrin SJ, Sowalsky AG, Balk SP, Ye H.

Prostate. 2016 Sep;76(13):1227-36. doi: 10.1002/pros.23212. Epub 2016 Jun 8.

47.

State of the science on prevention and screening to reduce melanoma incidence and mortality: The time is now.

Tripp MK, Watson M, Balk SJ, Swetter SM, Gershenwald JE.

CA Cancer J Clin. 2016 Nov 12;66(6):460-480. doi: 10.3322/caac.21352. Epub 2016 May 27. Review.

48.

Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy.

Li Z, Alyamani M, Li J, Rogacki K, Abazeed M, Upadhyay SK, Balk SP, Taplin ME, Auchus RJ, Sharifi N.

Nature. 2016 May 26;533(7604):547-51. doi: 10.1038/nature17954.

49.

SOX9 drives WNT pathway activation in prostate cancer.

Ma F, Ye H, He HH, Gerrin SJ, Chen S, Tanenbaum BA, Cai C, Sowalsky AG, He L, Wang H, Balk SP, Yuan X.

J Clin Invest. 2016 May 2;126(5):1745-58. doi: 10.1172/JCI78815. Epub 2016 Apr 4.

50.

ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer.

Gao S, Ye H, Gerrin S, Wang H, Sharma A, Chen S, Patnaik A, Sowalsky AG, Voznesensky O, Han W, Yu Z, Mostaghel EA, Nelson PS, Taplin ME, Balk SP, Cai C.

Clin Cancer Res. 2016 Jul 15;22(14):3672-82. doi: 10.1158/1078-0432.CCR-15-2309. Epub 2016 Mar 2.

Supplemental Content

Support Center